The radiotracer [89Zr]Zr-DFO-IMAB027 showed high contrast when visualizing CLDN6-expressing xenografts for PET imaging, and [177Lu]Lu-DOTA-IMAB027 induced rapid tumor regression in both the TE-1-CLDN6 and the CLDN6-PDX models. This research has implications for improving the radioligand diagnosis and treatment of EC.

10 months ago

Journal

CLDN6 (Claudin 6)

ASP1650

over3years

A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors. (PubMed, Invest New Drugs)

CLDN6 expression seems ubiquitous in all elements of GCT and is worthy of investigation as a diagnostic biomarker and therapeutic target. (Clinical trial information: NCT03760081).

over 3 years ago

P2 data • Journal

CLDN6 (Claudin 6)

CLDN6 expression • CLDN6 positive

ASP1650

4years

Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR) (clinicaltrials.gov)

P1, N=42, Completed, Ganymed Pharmaceuticals GmbH | N=72 --> 42

4 years ago

Clinical • Enrollment change

MUC16 (Mucin 16, Cell Surface Associated) • CLDN6 (Claudin 6)

ASP1650

5years

A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors (clinicaltrials.gov)

P2, N=19, Completed, Astellas Pharma Global Development, Inc. | Recruiting --> Completed | N=46 --> 19 | Trial completion date: Feb 2021 --> Oct 2020 | Trial primary completion date: Feb 2021 --> Oct 2020

5 years ago

Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date

AFP (Alpha-fetoprotein)

ASP1650

5years

A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors (clinicaltrials.gov)

P2, N=46, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Oct 2022 --> Feb 2021 | Trial primary completion date: Sep 2022 --> Feb 2021

5 years ago

Clinical • Trial completion date • Trial primary completion date

AFP (Alpha-fetoprotein)

ASP1650

over5years

A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors (clinicaltrials.gov)

P2, N=46, Recruiting, Astellas Pharma Global Development, Inc. | Active, not recruiting --> Recruiting

over 5 years ago

Clinical • Enrollment open

AFP (Alpha-fetoprotein)

ASP1650